Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children11010.24287/1726-1708-2015-14-3-39-47ACUTE LEUKEMIAОСТРЫЙ ЛЕЙКОЗThromboses in children with acute lymphoblastic leukemiaТромбозы у детей с острым лимфобластным лейкозомZharikovaL. I.ЖариковаЛ. И.
Russian Federation
RumyantsevaYu. V.РумянцеваЮ. В.
Russian Federation
j.roumiantseva@mail.ruKarachunskyA. I.КарачунскийА. И.
Russian Federation
aikarat@mail.ruFederal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry RogachevФедеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава РоссииRussian National Research Medical University named after N.I.PirogovРоссийский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России19092015143394719092018Copyright ©; 2015, «D. Rogachev NMRCPHOI»Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2015«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/110

Progress in modern research led to improvement of event-free survival of children with acute lymphoblastic leukemia (ALL), which now reached 80% and higher. Lethal cases today are most often caused by side effects of therapy. Hence, further improvement of the results of ALL treatment in children implies effective prevention and therapy of complications and reduction of the toxicities of therapies. One of hazardous complications of ALL therapy, deteriorating the results of treatment and, hence, the patients’ survival, is thrombosis - life-time blood clotting in the vascular lumen or heart cavities. This paper presents published data on the incidence, pathogenesis, risk factors, diagnosis, and potentialities of modern therapies for this grave complication and its prevention.

Успехи современной науки привели к тому, что бессобытийная выживаемость детей с острым лимфобластным лейко- зом (ОЛЛ) составляет более 80%. Летальные случаи заболевания в настоящее время чаще всего связаны с осложне- ниями терапии. Соответственно, дальнейшее улучшение результатов лечения ОЛЛ у детей может быть обеспечено, прежде всего, за счет эффективных методов профилактики и лечения осложнений, а также за счет снижения токсич- ности применяемых программ терапии. Одним из опасных осложнений терапии ОЛЛ, оказывающих неблагоприятное влияние на результаты лечения и, как следствие, на выживаемость пациентов, является тромбоз - прижизненное образование сгустков крови в просвете сосудов или в полостях сердца. В статье, представляющей собой обзор лите- ратуры, представлены данные о частоте, патогенезе, факторах риска, диагностике, возможностях современной тера- пии и профилактики этого грозного осложнения.

детиострый лимфобластный лейкозтромбозL-аспарагиназатромбофилияглюкокортикостероидыцентральный венозный катетерантикоагулянтынизкомолекулярные гепариныchildrenacute lymphoblastic leukemiathrombosisL-asparaginasethrombophiliaglucocorticosteroidscentral venous catheteranticoagulantslow molecular weight heparinSchrappe M, Stanulla M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):52-63Barnes E. Caring and curing: paediatric cancer services since 1960. Eur J Cancer Care (Engl). 2005;14(14):373-80Румянцева ЮВ, Карачунский АИ, Румянцев АГ. Оптимизация терапии острого лимфобластного лейкоза у детей в России. Педиатрия. Журнал им. ГН Сперанского. 2009;87(4):19-27./Rumyantseva YuV, Karachunskiy AI, Rumyantsev AG. Optimizatsiya terapii ostrogo limfoblastnogo leykoza u detey v Rossii. Pediatriya. Zhurnal im. GN Speranskogo. 2009;87(4):19-27. (In Russian)Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol. 2007;138(4):430-45Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009; 27(29):4919-26Mitchell L, Lambers M, Flege S, Kenet G, Li-Thiao-Te V, Holzhauer S, et al. Validation of a predictive model for identifying an increased risk for thrombo- embolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood. 2010;115(24):4999-5004Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta- analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108(7):2216-22Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore).1977;56(1):1-37Bick RL. Cancer-associated thrombosis. N Engl J Med. 2003;349(2):109-11Giannakopoulos B, Krilis SA. How I treat the antiphospholipid syndrome. Blood. 2009;114(10):2020-30Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-509Zia AN, Chitlur M. Management of thrombotic complications in acute lymphoblastic leukemia. Indian J Pediatr. 2013;80(10):853-62Bushman JE, Palmieri D, Whinna HC, Church FC. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2000;24(7):559-65Nowak-Göttl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood. 2003; 101(7):2529-33Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol. 2005;129(6):803-10Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol. 2009;22(1):103-14Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251-7Kuhle S, Massicotte P, Chan A, Adams M, Abdolell M, de Veber G, et al. Systemic thromboembolism in children. Data from the 1-800-NO-CLOTS Consultation Service. Thromb Haemost. 2004;92(4):722-8Ku YH, Kuo PH, Tsai YF, Huang WT, Lin MH, Tsao CJ. Port-A-Cath implantation using percutaneous puncture without guidance. Ann Surg Oncol. 2009;16(3): 729-34Zganjer M, Cizmić A, Butković D, Matolić M, Karaman-Ilić M, Stepan J. Central venous catheters for chemotherapy of solid tumors--our results in the last 5 years. Coll Antropol. 2008;32(3):767-70Yeste Sánchez L, Galbis Caravajal JM, Fuster Diana CA, Moledo Eiras E. Protocol for the implantation of a venous access device (Port-A-Cath System). The com- plications and solutions found in 560 cases. Clin Transl Oncol. 2006;8(10): 735-41Ahmed Z, Mohyuddin Z. Complications associated with different insertion techniques for Hickman catheters. Postgrad Med J. 1998;74(868):104-7Гилевич АВ, Кулагин АД, Крючкова ИВ, Сергеевичева ВВ, Сизикова СА, Труфакин СВидр. Проблема обеспечения венозного доступа в онкогемато- логии. Интенсивная терапия. 2007;3. Режим доступа: http://icj.ru/journal/ number-3-2007/124-problema-obespecheniya-venoznogo-dostupa-v- onkogematologii.html./Gilevich AV, Kulagin AD, Kryuchkova IV, Sergeevicheva VV, Sizikova SA, Trufakin SV, et al. Problema obespecheniya venoznogo dostupa v onkogematologii. Intensivnaya terapiya. 2007;3. Available at: http://icj.ru/journal/ number-3-2007/124-problema-obespecheniya-venoznogo-dostupa-v- onkogematologii.html. (In Russian)McLean TW, Fisher CJ, Snively BM, Chauvenet AR. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol. 2005;23(13):3024-9Lee SH, Hahn ST. Comparison of complications between transjugular and axillosubclavian approach for placement of tunneled, central venous catheters in patients with hematological malignancy: a prospective study. Eur Radiol. 2005;15(6):1100-4Halton J, Nagel K, Brandão LR, Silva M, Gibson P, Chan A, et al. Do children with central venous line (CVL) dysfunction have increased risk of symptomatic thromboembolism compared to those without CVL-dysfunction, while on cancer therapy? BMC Cancer. 2012;12:314Samaras P, Dold S, Braun J, Kestenholz P, Breitenstein S, Imhof A, et al. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology. 2008;74(3-4):237-44Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clin Microbiol Infect. 2006;12(7):606-20Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, et al. Prospective evaluation of the thrombotic risk in children with acute lympho- blastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood. 1999;93(5): 1595-9Ranta S, Tuckuviene R, Mäkipernaa A, Albertsen BK, Frisk T, Tedgård U, et al. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology. Br J Haematol. 2015;168(4):547-52Piovesan D, Attard C, Monagle P, Ignjatovic V. Epidemiology of venous thrombosis in children with cancer. Thromb Haemost. 2014;111(6):1015-21Saedon M, Stansby G. Post-thrombotic syndrome: prevention is better than cure. Phlebology. 2010;25(Suppl.1):14-9Kahn SR. How I treat postthrombotic syndrome. Blood. 2009;114(21):4624-31Polen E, Weintraub M, Stoffer C, Jaffe DH, Burger A, Revel-Vilk S. Post-thrombotic syndrome after central venous catheter removal in childhood cancer survivors: A prospective cohort study. Pediatr Blood Cancer. 2015;62(2):285-90Athale U. Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Rev Hematol. 2013;6(5):599-609Kim FM, Burrows PE, Hoffer FA, Chung T. Interpreting the results of pediatric central venous catheter studies. Radiographics. 1996;16(4):747-54Sébire G, Tabarki B, Saunders DE, Leroy I, Liesner R, Saint-Martin C, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain. 2005;128(3):477-89Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein throm- bosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost. 2002;87(4):593-8Male C, Kuhle S, Mitchell L. Diagnosis of venous thromboembolism in children. Semin Thromb Hemost. 2003;29(4):377-90Kenet G, Kirkham F, Niederstadt T, Heinecke A, Saunders D, Stoll M, et al. Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. Lancet Neurol. 2007;6(7):595-603Баркаган ЗС. Гемостаз. В кн.: Воробьев АИ, ред. Руководство по гематологии. 3-е изд. М.: Ньюдиамед; 2005:9-148./Barkagan ZS. Gemostaz. V kn.: Vorob'yev AI (ed). Rukovodstvo po gematologii. 3-e izd. Moscow: "N'yudiamed" Publ.; 2005: 9-148. (In Russian)Monagle P, Ignjatovic V, Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev. 2010;24(2):63-8Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J Clin Oncol. 2010;28(32):4781-2Guyatt GH, Norris SL, Schulman S, Hirsh J, Eckman MH, Akl EA, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2,Suppl.):53S-70SWhite RH. The epidemiology of venous thromboembolism. Circulation. 2003; 107(23,Suppl.1):14-8Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001-8Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362-72Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost. 2006;4(10):2280-2Newall F, Johnston L, Ignjatovic V, Summerhayes R, Monagle P. Age-related plasma reference ranges for two heparin-binding proteins--vitronectin and platelet factor 4. Int J Lab Hematol. 2009;31(6):683-7Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost. 2010;8(6):1290-4Haroon Y, Shearer MJ, Rahim S, Gunn WG, McEnery G, Barkhan P. The content of phylloquinone (vitamin K1) in human milk, cows’ milk and infant formula foods deter- mined by high-performance liquid chromatography. J Nutr. 1982;112(6): 1105-17von Kries R, Shearer M, McCarthy PT, Haug M, Harzer G, Göbel U. Vitamin K1 content of maternal milk: influence of the stage of lactation, lipid composition, and vitamin K1 supplements given to the mother. Pediatr Res. 1987;22(5):513-7Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health. 2003;39(4):289-92Garcia DA, Baglin TP, Weitz JI, Samama MM; American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2,Suppl.):e24S-43SIgnjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-factor Xa assay is appropriate? Thromb Res. 2007;120(3):347-51Newall F, Ignjatovic V, Summerhayes R, Gan A, Butt W, Johnston L, et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res. 2009;123(5):710-4Merkel N, Gunther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol. 2006;115(3-4): 230-6Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children. Br J Haematol. 2010;149(5):734-8Nowak-Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008;153(6):1120-7Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F365-70Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, et al. Dose- finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2005;94(6):1164-71Massicotte MP, Adams M, Leaker M, Andrew M. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE). Thromb Haemost. 1997; 78(Suppl.1):282. AbstrMassicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al. Dose- finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003; 109(2-3):93-9Nohe N, Flemmer A, Rümler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr. 1999;158(Suppl.3):S134-9Andrew M, Marzinotto V, Brooker LA, Adams M, Ginsberg J, Freedom R, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost. 1994;71(3):265-9Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999;94(9):3007-14Newall F, Savoia H, Campbell J, Monagle P. Anticoagulation clinics for children achieve improved warfarin management. Thromb Res. 2004;114(1):5-9Ranta S, Heyman MM, Jahnukainen K, Taskinen M, Saarinen-Pihkala UM, Frisk T, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2013;24(7):749-56Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90(2):235-44Albisetti M. Thrombolytic therapy in children. Thromb Res. 2006;118(1):95-105Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12(4):R105Avila ML, Macartney CA, Hitzler JK, Williams S, Kiss A, Brandão LR. Assessment of the outcomes associated with periprocedural anticoagulation management in children with acute lymphoblastic leukemia. J Pediatr. 2014;164(5):1201-7Reed RA, Teitelbaum GP, Stanley P, Mazer MJ, Tonkin IL, Rollins NK. The use of inferior vena cava filters in pediatric patients for pulmonary embolus prophylaxis. Cardiovasc Intervent Radiol. 1996;19(6):401-5Raffini L, Cahill AM, Hellinger J, Manno C. A prospective observational study of IVC filters in pediatric patients. Pediatr Blood Cancer. 2008;51(4):517-20Chaudry G, Padua HM, Alomari AI. The use of inferior vena cava filters in young children. J Vasc Interv Radiol. 2008;19(7):1103-6Menon SC, Hagler DJ, Cetta F, Cabalka AK. Rheolytic mechanical thrombectomy for pulmonary artery thrombus in children with complex cyanotic congenital heart disease. Catheter Cardiovasc Interv. 2008;71(2):237-43Sur JP, Garg RK, Jolly N. Rheolytic percutaneous thrombectomy for acute pulmonary embolism in a pediatric patient. Catheter Cardiovasc Interv. 2007; 70(3):450-3Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012;129(4):407-17Tokgoz H, Caliskan U, Demir M. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2012;23(8): 769-71Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther. 2012;17(1):12-30Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007;27(4):564-87Rayapudi S, Torres A Jr, Deshpande GG, Ross MP, Wohrley JD, Young G, et al. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer. 2008;51(6): 798-801Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol. 2013;20(5):430-6Streif W, Ageno W. Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children. Wien Med Wochenschr. 2011;161(3-4):73-9Mahan CE. Practical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolism treatment. J Thromb Thrombolysis. 2015;39(3):295-303Monagle P, Chan AK, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2, Suppl.):e737S- 801Svan Ommen CH, Chan AK. Supportive care in pediatric cancer: the road to prevention of thrombosis. Semin Thromb Hemost. 2014;40(3):371-81